2011
DOI: 10.1007/s12088-011-0233-z
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Study of Bacillus coagulans Unique IS-2 (ATCC PTA-11748) in the Treatment of Patients with Bacterial Vaginosis

Abstract: Bacterial vaginosis (BV) is the most prevalent vaginal infection worldwide and is characterized by reduction of native lactobacilli. Antimicrobial therapy used to cure the disease is often found to be ineffective. We postulate that Bacillus coagulans Unique IS-2 (Unique Biotech Limited, India) might provide an appendage to antimicrobial treatment and improve curing rate. In the present study 40 Indian women diagnosed with BV by the presence of symptoms including white discharge, pH greater than 4.7, burning mi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
16
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 35 publications
(17 citation statements)
references
References 13 publications
1
16
0
Order By: Relevance
“…Bacillus coagulans Unique IS2 TM (MTCC 5260, ATCC PTA-11748) is a spore forming, non-toxic commercial probiotic strain 23,24 . The clinical trials conducted on anti-hypercholesterolemic effect 25 , liver cirrhosis 26 , bacterial vaginosis 27 , acute-diarrhea 28 , abdominal pain 29 , constipation 30 , oral health 31 and IBS in children 22 have proven therapeutic efficacy and safety of this strain. Moreover, in vitro studies on anti-inflammatory and immune-modulatory activity 32 , anti-proliferative effects in colon cancer cells 33 , and in vivo anti-inflammatory effects in animal model 34 strengthen the therapeutic applicability.…”
Section: Discussionmentioning
confidence: 99%
“…Bacillus coagulans Unique IS2 TM (MTCC 5260, ATCC PTA-11748) is a spore forming, non-toxic commercial probiotic strain 23,24 . The clinical trials conducted on anti-hypercholesterolemic effect 25 , liver cirrhosis 26 , bacterial vaginosis 27 , acute-diarrhea 28 , abdominal pain 29 , constipation 30 , oral health 31 and IBS in children 22 have proven therapeutic efficacy and safety of this strain. Moreover, in vitro studies on anti-inflammatory and immune-modulatory activity 32 , anti-proliferative effects in colon cancer cells 33 , and in vivo anti-inflammatory effects in animal model 34 strengthen the therapeutic applicability.…”
Section: Discussionmentioning
confidence: 99%
“…It shares certain characteristics including the outstanding ability of lactic acid production ( Juturu and Wu, 2017 ). It has been demonstrated to show a positive effect in the treatment of irritable bowel syndrome ( Majeed et al, 2015 ), bacterial vaginosis ( Ratna et al, 2012 ), and gingivitis ( Alkaya et al, 2016 ) by several clinical trials. In this communication, we reported a Bacillus isolates with predominant ability to produce L-lactic acid and also evaluated its properties to use as a potential probiotic.…”
Section: Introductionmentioning
confidence: 99%
“…Bacillus coagulans has also been shown to be effective in the form of a synbiotic in improving symptoms of irritable bowel syndrome and childhood functional abdominal pain [ 26 , 27 ]. In a study of 40 Indian women, Bacillus coagulans , as an adjunct to antibiotic therapy has been demonstrated to have a positive effect in the treatment of bacterial vaginosis [ 28 ]. Bacillus coagulans has also been demonstrated to reduce symptoms of Clostridium difficile -induced colitis in mice [ 29 , 30 ].…”
Section: Introductionmentioning
confidence: 99%